RJA
ACRV icon

Raymond James & Associates’s Acrivon Therapeutics ACRV Stock Holding History

Raymond James & Associates’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,200
Closed -$72.9K – 3952
2024
Q1 		$72.9K Buy
+10,200
New +$47.3K ﹤0.01% 3769

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James & Associates's ACRV Position: Q2 2024 in Review

Raymond James & Associates sold out of Acrivon Therapeutics (ACRV) in Q2 2024, closing a stake of 10,200 shares — an estimated $72.9K sold.

Raymond James & Associates first reported a position in ACRV in Q1 2024 and held it in 1 quarter. The position peaked at $72.9K in Q1 2024. 55 funds tracked by Wall St. Rank hold ACRV as of Q2 2024.

  • Raymond James & Associates reported no remaining Acrivon Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 10,200 Acrivon Therapeutics shares in Q2 2024, an estimated $72.9K.
  • Raymond James & Associates first reported a position in Acrivon Therapeutics in Q1 2024 and held it in 1 quarter.
  • Raymond James & Associates's Acrivon Therapeutics position peaked at $72.9K in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.